GO
Loading...

Enter multiple symbols separated by commas

Bristol-Myers Squibb Co

More

  • *CEO says Roche committed to Switzerland despite franc rise. While cross-town rival Novartis has said it will review its Swiss cost base, Roche Chief Executive Severin Schwan said his company had no plans to move operations. "I continue to believe that Switzerland and Basel offer a very good framework for our business," Schwan told reporters.

  • *Apple, P&G, Stryker also see headwinds. NEW YORK, Jan 27- A slew of U.S. multinational companies, from DuPont to Procter& Gamble, showed that a strong U.S. dollar hurt their earnings, and several blue-chip exporters said the situation will get worse if the greenback holds its strength. The pain is hitting multiple sectors, including industrial companies such as 3 M Co,...

  • *Apple also at risk; Microsoft shares plummet on currency concern. NEW YORK, Jan 27- A slew of U.S. multinational companies from DuPont to Microsoft Corp showed that a strong U.S. dollar is hammering their earnings, with several blue chip exporters predicting the situation will get worse if the greenback holds its strength. The pain is hitting multiple sectors...

  • Midday movers: Lockheed Martin, Plantronics & more Tuesday, 27 Jan 2015 | 1:05 PM ET
    Wall Street subway station NYSE

    Some of Tuesday's midday movers:

  • Bristol-Myers quarterly profit beats forecasts Tuesday, 27 Jan 2015 | 9:22 AM ET
    Bristol-Myers Squibb R&D headquarters.

    Bristol-Myers Squibb reported higher-than-expected earnings, helped by strong sales of its hepatitis C drugs and its Eliquis blood clot preventer.

  • Jan 27- Bristol-Myers Squibb Co on Tuesday said profits could fall as much as 16 percent in 2015, a worse forecast than Wall Street had expected, as the stronger dollar takes a toll on U.S. drugmakers. Bristol-Myers, whose shares fell almost 2 percent in premarket trading, said it earned $13 million, or 1 cent per share, in the fourth quarter. Revenue fell 4 percent to...

  • Dow futures off nearly 300 points after data miss Tuesday, 27 Jan 2015 | 9:05 AM ET
    A line of snow plows prepares to battle the blizzard on Lexington Ave in New York City on Jan. 26, 2015.

    U.S. stock index futures signaled a sharply lower open as major U.S. corporates missed fourth quarter earnings expectations.

  • Bristol-Myers quarterly profit beats forecasts Tuesday, 27 Jan 2015 | 7:56 AM ET

    Jan 27- Bristol-Myers Squibb Co reported higher-than-expected quarterly earnings, helped by surprisingly strong sales of its hepatitis C drugs and its Eliquis blood clot preventer. The U.S. drugmaker on Tuesday said it earned $13 million, or 1 cent per share, in the fourth quarter. Revenue fell 4 percent to $4.26 billion, coming in above Wall Street expectations...

  • Lightning Round: Only private equity I recommend Thursday, 22 Jan 2015 | 7:44 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Early movers: UNH, AAPL, NSP, NFLX, AMD & more Wednesday, 21 Jan 2015 | 8:05 AM ET

    Some of the names on the move ahead of the open.

  • Bristol-Meyers Squibb taps a doctor as new CEO Tuesday, 20 Jan 2015 | 5:29 PM ET
    Bristol-Myers Squibb R&D headquarters.

    Pharmaceutical giant Bristol-Myers Squibb named Dr. Giovanni Caforio as its new CEO on Tuesday.

  • Cramer: Forget Switzerland! Make big bucks in USA Thursday, 15 Jan 2015 | 6:14 PM ET
    Americans American flag

    How could a country famous for chocolate take down the market? Jim Cramer thinks investors should stay domestic.

  • *AstraZeneca sees $3.5 bln sales, analysts' numbers lower. *AstraZeneca shares up 1.5 percent. LONDON, Jan 14- AstraZeneca's blood-thinning drug Brilinta cut the risk of death or heart attack in patients with a history of previous attacks, according to a major clinical trial that will boost hopes for the closely watched product.

  • *AstraZeneca shares up 1.5 percent. LONDON, Jan 14- AstraZeneca's blood-thinning drug Brilinta cut the risk of death or heart attack in patients with a history of previous attacks, according to a major clinical trial that will boost hopes for the product. But AstraZeneca Chief Executive Pascal Soriot has made it a top priority and the company flagged Brilinta's...

  • Lightning Round: Sweet spot of the marketplace Monday, 12 Jan 2015 | 7:04 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • 11 ways to play biotech Monday, 12 Jan 2015 | 6:59 PM ET
    Biotech

    Traders on CNBC's "Fast Money" outlined their strongest plays in the ever-volatile biotechnology space.

  • Your first trade for Tuesday Monday, 12 Jan 2015 | 6:23 PM ET
    Fast Money Final Trade: FXC, EWZ, M, TLT

    The "Fast Money" traders give their final trades of the day.

  • US stocks end lower with crude; Alcoa reports Monday, 12 Jan 2015 | 4:08 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks dropped Monday after a second weekly loss.

  • *Foundation Medicine jumps; Roche to take majority stake. Oil prices continued their downward march and weighed on equities, with both Brent and U.S. crude down about 4 percent as Goldman Sachs slashed its short-term price forecasts and Gulf producers showed no signs of curbing output. "During this cycle, since the beginning of the precipitous selloff in the...

  • *Foundation Medicine jumps; Roche to take majority stake. Oil prices continued their downward march and helped weaken futures, with Brent down 3.8 percent to $48.20 and U.S. crude down 3.7 percent to $46.59 as Goldman Sachs slashed its short-term price forecasts and Gulf producers showed no signs of curbing output. "During this cycle, since the beginning of the...